A Pediatric Phase 1 Trial Of Vorinostat And Temozolomide In Relapsed Or Refractory Primary Brain Or Spinal Cord Tumors: A Children’s Oncology Group Phase 1 Consortium Study

PURPOSE: We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hummel, Trent R., Wagner, Lars, Ahern, Charlotte, Fouladi, Maryam, Reid, Joel M., McGovern, Renee M., Ames, Matthew M., Gilbertson, Richard J., Horton, Terzah, Ingle, Ashish M., Weigel, Brenda, Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4139006/
https://ncbi.nlm.nih.gov/pubmed/23554030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24541
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados